TG4001 Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers Read the press release – Download the presentation Watch our analyst call discussing the results
Author: alcyon
Transgene R&D Day (Paris, France)
Lien
annonceR&D
Find Out How Transgene’s Virus Powered ImmunotherapiesCan Transform the Treatment of Solid Tumors R&D Day – ParisSeptember 27, 2022 Detailed Program – Watch the webcast – Presentation
TG4050
TG4050 TG4050 is an individualized therapeutic vaccine A particularly innovative immunotherapy, TG4050 is the lead myvac ® candidate. –> article annonce 28362 ou substitut 28368 Collaboration agreements Transgene has signed a strategic collaboration agreement with NEC for the development of TG4050, the first candidate derived from the myvac® platform. This personalized immunotherapy is developed for each… Continue reading TG4050
annonce TG4050en
First positive data from Phase I clinical trials Initial data presented at the ASCO congress (June 2022) Press release [PDF] Poster Interview of the team and Pr Ottensmeier on the data (November 2022) Listen to the webcast with Prof Delord (in French) Listen to the webcast with Pr Ottensmeier (in English) One cancer, one… Continue reading annonce TG4050en
in a nutshell
Transgene in a nutshell Download (PDF)
Carol Stuckley
Independent Director Carol Stuckley brings more than 35 years of experience as a strategic and international financial executive, with proven success leading finance teams and creating shareholder value for healthcare companies. She currently serves as a Board Director and Chairperson of the audit committee of Centessa Pharmaceuticals, plc and previously served on the board of… Continue reading Carol Stuckley
Prof. Jean-Yves Blay
Independent Director, Chairman of the Clinical Development Committee Jean-Yves Blay is Professor of Medical Oncology and has been General Director of the Léon Bérard Center in Lyon since 2014. He holds a PhD obtained in 1994 from the Claude Bernard University in Lyon and has been authorized to supervise research since 1996. He currently leads… Continue reading Prof. Jean-Yves Blay
Dr. Alessandro Riva
Chairman and CEO Dr. Riva has nearly 30 years’ experience in the Life Sciences industry. He was CEO of Intima Bioscience which specializes in cell therapies for solid cancers and was previously CEO of Ichnos Sciences. Dr Riva was also Executive Vice President (EVP), Global Head of Oncology Therapeutics and Cell & Gene Therapy at… Continue reading Dr. Alessandro Riva
Ethics and compliance
Transgene, in the conduct of its activities, aims to act with integrity and in full compliance with its regulatory and legal environment. Transgene has set up a compliance program addressing business ethics, the protection of personal data and including specific tools, such as a whistleblowing system. The Internal Audit department of Institut Mérieux, Transgene’s parent company,… Continue reading Ethics and compliance